Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS

This study tests a new CAR-T cell therapy called ARD103 in people whose acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) has come back or stopped responding to treatment. CAR-T therapy re-engineers your own immune cells to recognize and destroy cancer cells. **You may be eligible if...** - You have been diagnosed with AML that has relapsed or is not responding to treatment, or MDS with at least 5% blast cells in the bone marrow - You are in good physical condition (ECOG 0 or 1) - Your kidneys, liver, and heart are functioning adequately **You may NOT be eligible if...** - You have an active, uncontrolled infection (including HIV) - You have serious organ failure - You are pregnant or unwilling to use contraception - You have previously received certain types of cell or gene therapy targeting the same protein Talk to your doctor to see if this trial is right for you.